Giménez, Marga
Bellido, Virginia
Quirós, Carmen
Conget, Ignacio
Gros Herguido, Noelia
Roca, Daria
Pérez-Morales, Ana
van den Heuvel, Tim
Juachon, Maria Joanna
Petrovski, Goran
Funding for this research was provided by:
Medtronic Europe
Article History
Received: 19 January 2026
Accepted: 8 May 2026
First Online: 30 June 2026
Declarations
:
: Marga Giménez discloses that she has received payments as a speaker or to participate in advisory board meetings from Medtronic. Virginia Bellido has acted as a consultant/advisor for Abbott Diabetes Care, AstraZeneca, Bayer, Boehringer Ingelheim, Dexcom, Eli Lilly, Merck, Novo Nordisk, and Sanofi; acted as a speaker for Abbott Diabetes Care, AstraZeneca, Bayer, Boehringer Ingelheim, Dexcom, Eli Lilly, Merck, Novo Nordisk, and Sanofi; and carried out research activities for Abbott Diabetes Care, Eli Lilly, Novo Nordisk, and Sanofi. Tim van den Heuvel, Maria Joanna Juachon, and Goran Petrovski are employees of Medtronic. Carmen Quirós, Ignacio Conget, Noelia Gros Herguido, Daria Roca, and Ana Pérez-Morales, have nothing to disclose.
: The study was conducted in accordance with the Declaration of Helsinki (1964) and its subsequent amendments. Ethics committee approval was not required for this study as this study was a real-world analysis, and therefore deemed to not qualify as “human subjects research”. All CareLink™ Personal account holders are proactively asked to provide consent for the use of their de-identified data by Medtronic for research purposes. Users who did not provide consent were excluded from the analyses, and all data were analyzed only after de-identification.